January 1, 2004 |
A federal judge in San Francisco on Wednesday upheld Allergan Inc.'s patent for its top-selling eye drug Acular, blocking Apotex Inc. from selling a competing product. The ruling may help Allergan in a government antitrust investigation. U.S. District Judge Martin Jenkins said Apotex could not sell a generic version of Acular until Allergan's patent expired in 2009. Acular is used to treat allergy, photophobia, post-surgical pain and post-surgical inflammation.
May 30, 1991 |
More than a year ago, sister drug companies in the United States and Canada first laid plans to enter the health marketplace with a low-cost generic equivalent for the most widely used AIDS drug, AZT. Now, with the federal government adding weight to their efforts to break the monopoly held by AZT's manufacturer, Burroughs Wellcome Co., they may get the chance, slicing the cost of the life-extending drug as much as 75% in the process.
August 15, 2006 |
Bristol-Myers Squibb Co. and Sanofi-Aventis said Monday that they filed for an injunction against Apotex Corp. to stop the Canadian drug maker from selling a less expensive, generic version of blood thinner Plavix and force it to recall product already sold. The companies also said they had begun discounting Plavix to stem the loss of market share. A hearing on the motion is set for Friday in the U.S.
December 9, 2006 |
A federal appeals court upheld Friday an injunction preventing Apotex Corp. from selling its generic version of Plavix, a blockbuster blood thinner marketed by Bristol-Myers Squibb and Sanofi-Aventis. The U.S. Court of Appeals for the Federal Circuit in Washington upheld the injunction issued in August by the U.S. District Court for the Southern District of New York.
June 6, 2006 |
Allergan Inc., maker of the Botox wrinkle treatment, said the Food and Drug Administration approved its Juvederm dermal filler treatment targeting the folds alongside the nose and mouth. Separately, Allergan said it won a court ruling that would block Apotex Inc. from selling a generic version of a treatment for eye inflammation until 2009.
May 31, 2007 |
Bristol-Myers Squibb Co. was charged with lying to federal regulators over the bungled patent settlement for the drug maker's blood-thinner Plavix, a planned first step toward it pleading guilty in the case. A two-count criminal charge was filed in federal court in Washington. The company said May 10 that it would plead guilty to two counts of making false statements and pay a $1-million fine.